PD-L1/B7-H1/CD274 recombinant protein

Recombinant Human PD-L1/B7-H1/CD274 Protein (C-DYKDDDDK)

Cat. Num. AAA2553065

• Gene Names: CD274; B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1
• Purity: >95% as determined by reducing SDS-PAGE.
• Synonyms: PD-L1/B7-H1/CD274; Recombinant Human PD-L1/B7-H1/CD274 Protein (C-DYKDDDDK); Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1; PD-L1/B7-H1/CD274 recombinant protein

• Host: Human Cells
• Purity/Purification: >95% as determined by reducing SDS-PAGE.
• Form/Format: Lyophilized from a 0.2 mum filtered solution of 20mM PB 150mM Nacl pH 7.4.
• Sequence Positions: Phe19-Thr239
• Sequence Length: 176

• Species: Human
• Endotoxin: <1.0 EU per ug as determined by LAL test.
• Fusion Tag: C-DYKDDDDK
• Preparation and Storage: Lyophilized protein should be stored at < -20 degree C, though stable at room temperature for 3 weeks.; Reconstituted protein solution can be stored at 4-7 degree C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 degree C for 3 months.

Related Product Information for PD-L1/B7-H1/CD274 recombinant protein

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

NCBI and Uniprot Product Information

• NCBI GI #: 390979639
• NCBI GeneID: 29126
• NCBI Accession #: NP_001254635.1
• NCBI GenBank Nucleotide #: NM_001267706.1
• UniProt Accession #: Q9NZQ7; Q14CJ2; Q2V8D5; Q66RK1; Q6WEX4; Q9NUZ5; B2RBA2; B4DU27
• Molecular Weight: Molecular Mass: 26.3 kDa; Actual Protein Molecular Mass: 35-40 kDa
• NCBI Official Full Name: programmed cell death 1 ligand 1 isoform b
• NCBI Official Synonym Full Names: CD274 molecule
• NCBI Official Symbol: CD274
• NCBI Official Synonym Symbols: B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1
• NCBI Protein Information: programmed cell death 1 ligand 1
• UniProt Protein Name: Programmed cell death 1 ligand 1
• UniProt Gene Name: CD274
• UniProt Synonym Gene Names: PD-L12 PublicationsManual assertion based on opinion iniRef.10; PDCD1 ligand 1; Programmed death ligand 1; B7-H11 PublicationManual assertion based on opinion iniRef.1

NCBI Description

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

Uniprot Description

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).